Dr. Nastri is currently the Associate Vice President of Biotherapeutics at Incyte Corp. His group is responsible for end to end discovery and engineering of monoclonal and bispecific antibodies for oncology applications. His group uses both immunization as well as display approaches for the generation of lead molecules, which are further optimized by a combination of in vitro and in silico approaches.

Dr. Nastri started his career in the antibody field at Dyax Corp where he developed and co-invented key technologies utilized to build the Dyax Fab libraries. He then headed the Antibody Technologies group at EMD Serono where he implemented new approaches for selecting antibodies by single cell B-cloning and Phage Display. He became an Inventor of Avelumab, a clinical approved anti PD-L1 antibody.

He joined Pfizer CTI as a Biotherapeutic site head in NYC where he collaborated with local academic leaders to enable and advance novel therapeutic programs.

During his career Dr. Nastri became an inventor of multiple antibody therapeutic molecules and antibody discovery enable technologies while participate in a number of projects resulting in IND applications.